Date: 2013-05-31
Type of information:
phase: 1
Announcement: launch of the trial
Company: Cancer Research UK (UK)
Product: AZD3965
Action
mechanism: AZD3965 targets monocarboxylate transporter 1 (MCT1) which is essential in cell metabolism. Blocking this transporter limits cancer cells’ ability to generate energy, and decreases their capacity to survive.
The drug has been developed through Cancer Research UK\'s Clinical Development Partnerships (CDP) scheme. CDP is a joint initiative between Cancer Research UK’s DDO and Cancer Research Technology, to progress promising anti-cancer agents which pharmaceutical companies do not have the resources to progress, through early phase clinical trials.
Disease:
Therapeutic area: Cancer - Oncology
Country: UK
Trial details:
Latest
news: * On May 2013, Cancer Research UK\'s Drug Development Office (DDO) has launched a new clinical trial of AZD3965. The drug has been developed by AstraZeneca, and the trial will be undertaken by Cancer Research UK’s National Institute of Health Research (NIHR) Experimental Cancer Medicine Centre, based at the Northern Institute of Cancer Research at Newcastle University, as well as at least one other clinical centre. Approximately 63 cancer patients will take part in the first clinical trial of the compound to see if it is safe and can benefit cancer patients. Cancer Research UK’s DDO has collaborated closely with the trial clinical centres to plan, design and gain regulatory and ethical approval for this exciting first in class, first in man study. The DDO is sponsoring, funding and managing the trial whilst AstraZeneca is providing the drug. Under the terms of the agreement, AstraZeneca can decide if it wishes to develop the drug further based on the clinical trial data results at the end of the Phase I/IIa trial. If it chooses not to, the rights will be given to Cancer Research Technology to secure an alternative partner and ensure the drug has every possible chance of reaching patients. In either case, the charity will receive a share of any future revenues generated by the drug.AZD3965 is the fifth drug from Cancer Research UK\'s Clinical Development Partnerships (CDP) scheme to enter clinical trials. CDP is a joint initiative between Cancer Research UK’s DDO and Cancer Research Technology, to progress promising anti-cancer agents which pharmaceutical companies do not have the resources to progress, through early phase clinical trials. There are eight drugs in the CDP portfolio (AZD3965, DI-B4, CEN-209, AZD0424, GSK1070916A, IMA950, AT13148, IL17-E). The other drugs in clinical trials are AZD0424, GSK1070916A, IMA950 and AT13148, AZD-3965. Others trials are scheduled to open in 2013.
